First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO

被引：0
|
作者：
Rexer, H. [1 ]
Retz, M. [2 ]
Hammerer, P. [3 ]
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Tech Univ Munich, Urol Klin & Poliklin, Klinikum rdl, Munich, Germany
[3] Deutsch Krebsgesellschaft eV, Organgrp Arbeitsgemeinschaft Urol, Berlin, Germany
来源：
UROLOGE | 2021年 / 60卷 / 07期
关键词：
D O I：
10.1007/s00120-021-01570-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：987 / 988
页数：2
相关论文
共 50 条
  • [41] Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups
    Hong, Jun Hyuk
    Stenzl, Arnulf
    Szmulewitz, Russell Z.
    Petrylak, Daniel
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris Y.
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Baron, Benoit
    Haas, Gabriel P.
    Morlock, Robert
    Ramaswamy, Krishnan
    Armstrong, Andrew J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 102 - 103
  • [42] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
    Stenzl, A.
    Szmulewitz, R. Z.
    Petrylak, D. P.
    Holzbeierlein, J.
    Villers, A.
    Azad, A. A.
    Alcaraz, A.
    Alekseev, B. Y.
    Iguchi, T.
    Shore, N. D.
    Rosbrook, B.
    Baron, B.
    Haas, G. P.
    Morlock, R.
    Ramaswamy, K.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 332 - +
  • [43] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
    Alcaraz, A.
    Szmulewitz, R. Z.
    Shore, N.
    Crawford, E. D.
    Petrylak, D. P.
    Holzbeierlein, J.
    Villers, A.
    Azad, A. A.
    Alekseev, B.
    Iguchi, T.
    Gomez-Veiga, F.
    Rosbrook, B.
    Sugg, J.
    Haas, G. P.
    Stenzl, A.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S523 - S524
  • [44] Phase 3 Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: the ARCHES Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 10 - 12
  • [45] Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy thorn Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
    Francini, Edoardo
    Yip, Steven
    Ahmed, Shubidito
    Li, Haocheng
    Ardolino, Luke
    Evan, Carolyn P.
    Kaymakcalan, Marina
    Shaw, Grace K.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Alimohamed, Nimira S.
    Joshua, Anthony M.
    Heng, Daniel Y. C.
    Sweeney, Christopher J.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 130 - 134
  • [46] SURVIVAL ANALYSIS OF A RANDOMIZED PHASE III TRIAL COMPARING ANDROGEN DEPRIVATION THERAPY (ADT) PLUS DOCETAXEL VERSUS ADT ALONE IN HORMONE-SENSITIVE METASTATIC PROSTATE CANCER (GETUG-AFU 15/0403)
    Gravis, G.
    Fizazi, K.
    Lobbedez, F. Joly
    Oudard, S.
    Priou, F.
    Latorzeff, I.
    Delva, R.
    Krakowski, I.
    Laguerre, B.
    Rolland, F.
    Theodore, C.
    Deplanque, G.
    Ferrero, J. M.
    Pouessel, D.
    Mourey, L.
    Beuzeboc, P.
    Zanetta, S.
    Esterni, B.
    Habibian, M.
    Soulie, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 294 - 294
  • [47] Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.
    Francini, Edoardo
    Gray, Kathryn P.
    Evan, Carolyn
    Kaymakcalan, Marina D.
    Shaw, Grace Katherine
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses EDITORIAL COMMENT
    Smoragiewicz, Martin
    Emmenegger, Urban
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1370 - 1370
  • [49] OUTCOMES BY PROSTATE-SPECIFIC ANTIGEN LEVEL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY AND IMPLICATIONS FOR CLINICAL PRACTICE
    Huebner, Tamara
    Williams, Monique
    Shore, Neal
    El-Chaar, Nader
    Russell, David
    Armstrong, Andrew
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [50] SAABR: Single arm phase II study of abiraterone plus atezolizumab plus GnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)
    Rathkopf, D. E.
    Decker, B.
    Schum, P.
    McBride, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S672 - S672
12345